← All trials
NCT06736691
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2025
- Primary completion
- Sep 30, 2025
- Completion date
- Nov 30, 2025
- First posted
- Dec 17, 2024
- Last posted
- Dec 19, 2024
- Enrollment
- 315
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of BaselLead sponsor
- University of BaselOfficial
- BayerCollaborator
- University of BaselCollaborator
- Silicon Valley Community FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.